BAY 218
Alternative Names: BAY-218Latest Information Update: 28 Apr 2023
At a glance
- Originator Bayer
- Class Amides; Antineoplastics; Immunotherapies; Pyrazines; Small molecules
- Mechanism of Action Aryl hydrocarbon receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 29 Mar 2019 Preclinical trials in Cancer in Germany (PO) before March 2019
- 29 Mar 2019 Pharmacodynamics data from preclinical trials presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)